About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Precious Metal Time | Main | Bait And Switch For Type B GPCRs »

July 26, 2011

Data Handling in Collaborations

Email This Entry

Posted by Derek

I wanted to mention a book I've received, courtesy of the editors: Collaborative Computational Technologies for Biomedical Research. It's a multi-author look at various ways to handle data in all sorts of research partnerships - precompetitive consortia, academia-industrial collaborations, open-source discovery, and so on. Several levels of information are dealt with - patentable IP, raw data, notebook-sharing, etc.

Different readers will find different chapters of use - there's a lot of material covered here, with some unavoidable overlap - but anyone who's having to deal with these issues should definitely have a look.

Obligatory semi-regular note: that's an Amazon link, and this blog is an Amazon affiliate. Any purchases will send a small fee my way, which comes out of Amazon's hide, not yours.

Comments (5) + TrackBacks (0) | Category: Book Recommendations


1. StormBird on July 26, 2011 4:24 PM writes...

Thanks for posting this, Derek, it looks interesting even if the price is a bit steep in these straitened times. Since you mentioned pre-competitive consortia, I'd like to point your readers to the Pistoia Alliance ( which brings together Big Pharma, biotech, and software outfits. These guys are working together in both the chemistry and biology domains to exploit synergies in a a spirit of "coopetition". I have it on good authority that companies like GSK have put there best informatics guys on the project and I expect other companies have done likewise. With such an array of heavy-weights and IT leviathans, I think we'll see some real progress in this space in the coming year. Harbinger of a new paradigm, perhaps?

Permalink to Comment

2. Anonymous BMS Researcher on July 26, 2011 5:53 PM writes...

As various public and privat projects churn out many terabytes of data, lots of researchers in both industry and academia are thinking hard about collaborative approaches to mining such data. The traditional approach where everybody downloads a copy onto their own computers for analysis will be very costly when playing with such huge volumes of data.

Permalink to Comment

3. TJMC on July 27, 2011 1:14 PM writes...

Pharma's have enacted major investments and novel projects in this arena for at least the past 4-5 years. What is holding results back collaboratively is "messiness" due to the kinds of things we are seeing in Congress this week, but also due to differing views on intellectual property and what competitive advantages can be reaped.

But Stormbird is right - the toolsets are amazing and we have seen tremendous advances in disease modeling, collaborative R&D platforms and acceptance, but also in effective mining of combined data types ranging from chemical structures, to patents, to clinical information (often buried in prose - solvable by semantics.) Finally, these tools are no longer limited by storage or computing power, with cloud and decentralized supercomputers. Now we just have to solve the IP and brinkmanship issues.

Permalink to Comment

4. pagg stack on August 1, 2011 5:20 AM writes...

Am agree with your views and reviews, bio medical research is so important.

Permalink to Comment

5. pagg ferris on August 11, 2011 5:25 AM writes...

I wish I had the book in my hand, The post was very informative.

Permalink to Comment


Remember Me?


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry